About Us.

The company behind the science.

About Aerpio

Aerpio Pharmaceuticals is a biopharmaceutical company focused on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye.

Our lead programs include a Tie2 activator for diabetic retinopathy (DR) and a hypoxia-inducible factor α (HIF-α) stabilizer for the treatment of inflammatory bowel disease. The lead compound for the Tie2 program, AKB-9778, recently completed a proof-of-concept, Phase 2a study (TIME-2). AKB-4924, the lead compound in our HIF-α stabilization program, has recently completed a Phase 1a study.

Advisory Board

Name Organization
Randall Johnson, PhD Oxford University
Peter Campochiaro, MD Johns Hopkins School of Medicine
Dietmar Vestweber, PhD Max Planck Institute
Chris Kontos, MD Duke University School of Medicine
Susan Quaggin, MD Northwestern University Feinberg School of Medicine
Robert Shalwitz, MD

Board Members

Caley Castelein, MD
Anupam Dalal, M.D.
Pravin U. Dugel, MD
Joseph Gardner, PhD
Chau Q. Khuong, PhD
Muneer Satter (Chairman)
Steven Prelack
Paul Weiss, PhD